Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

NCT01619839 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT01619839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01619839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Lead sponsor
Nektar Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2012
Completion date
September 30, 2013
Enrollment
296 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis of the knee